Sex steroids and cervical cancer

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3045-3054

  Hellberg, Dan ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Center of Clinical Research   (Sweden)

Author keywords

Cervical cancer; Estradiol; Oral contraceptives; Progesterone; Review; Steroids

Indexed keywords

ANDROGEN RECEPTOR; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR; SEX HORMONE;

CANCER RISK; CHILDBIRTH; DRUG EFFECT; DRUG USE; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; PAPILLOMAVIRUS INFECTION; PARITY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; UTERINE CERVIX CANCER; WART VIRUS;

ALPHAPAPILLOMAVIRUS; FEMALE; GONADAL STEROID HORMONES; HUMANS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84865693415     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Gustafsson L, Ponten J, Bergstrom R and Adami HO: International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 71(2): 159-165, 1997.
2. Gasparini R and Panatto D: Cervical cancer: from Hippocrates through Rigoni-Stern to zur Hausen. Vaccine 27(Suppl 1): A4-5, 2009.
3. Laara E, Day NE and Hakama M: Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lance t 1(8544): 1247-1249, 1987.
4. Hakama M and Rasanen-Virtanen U: Effect of a mass screening program on the risk of cervical cancer. Am J Epidemiol 103(5): 512-517, 1976.
5. Fidler HK, Boyes DA and Worth AJ: Cervical cancer detection in British Columbia. A progress report. J Obstet Gynaecol Br Commonw 75(4): 392-404, 1968.
6. Nyberg R, Tornberg B and Westin B: Colposcopy and Schiller's iodine test as an aid in the diagnosis of malignant and premalignant lesions of the squamous epithelium of the cervix uteri. Acta Obstet Gynecol Scand 39: 540-556, 1960.
7. Seybolt GF and Papanicolau GN: Exfoliative cytology: its value in the diagnosis of cancer. Arch Med Cuba 4(6): 579-586, 1953.
8. zur Hausen H, Gissmann L, Steiner W, Dippold W, and Dreger I: Human papilloma viruses and cancer. Bibl Haematol 43: 569-571, 1975.
9. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ and Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6): 518-527, 2003.
10. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP and Young LS: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357(9271): 1831-1836, 2001.
11. Hellberg D and Stendahl U: The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer. Anticancer Res 25(4): 3041-3046, 2005.
12. Burd EM: Human papillomavirus and cervical cancer. Clin Microbiol Rev 16(1): 1-17, 2003.
13. De Palo G: Cervical precancer and cancer, past, present and future. Eur J Gynaecol Oncol 25(3): 269-278, 2004.
14. Wynder EL, Cornfield J, Schroff PD and Doraiswami KR: A study of environmental factors in carcinoma of the cervix. Am J Obstet Gynecol 68(4): 1016-1047; discussion, 48-52, 1954.
15. Hellberg D, Valentin J and Nilsson S: Smoking as risk factor in cervical neoplasia. Lancet 2(8365-66): 1497, 1983.
16. Brinton LA, Reeves WC, Brenes MM, Herrero R, de Britton RC, Gaitan E, Tenorio F, Garcia M and Rawls WE: Parity as a risk factor for cervical cancer. Am J Epidemiol 130(3): 486-496, 1989.
17. Hellberg D, Axelsson O, Gad A and Nilsson S: Conservative management of the abnormal smear during pregnancy. A long-term follow-up. Acta Obstet Gynecol Scand 66(3): 195-199, 1987.
18. Castellsague X and Munoz N: Chapter 3: Cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 31: 20-28, 2003.
19. Shaffer WL and Merrill JA: Carcinoma of the cervix associated with pregnancy. South Med J 62(8): 915-921, 1969.
20. Brinton LA, Hamman RF, Huggins GR, Lehman HF, Levine RS, Mallin K and Fraumeni JF Jr.: Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst 79(1): 23-30, 1987.
21. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, Angstrom T and Dillner J: Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intraepithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 82(7): 1332-1338, 2000.
22. Parazzini F, Chatenoud L, La Vecchia C, Negri E, Franceschi S and Bolis G: Determinants of risk of invasive cervical cancer in young women. Br J Cancer 77(5): 838-841, 1998.
23. Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, Hoang Anh PT, Ferreccio C, Matos E, Posso H, de Sanjose S, Shin HR, Sukvirach S, Lazcano-Ponce E, Ronco G, Rajkumar R, Qiao YL, Munoz N and Franceschi S: Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 15(11): 2148-2153, 2006.
24. Huss KS: Maternal diethylstilbestrol a time bomb for child? JAMA 218(10): 1564-1565, 1971.
25. Robboy SJ, Truslow GY, Anton J and Richart RM: Role of hormones including diethylstibestrol (DES) in the pathogenesis of cervical and vaginal intraepithelial neoplasia. Gynecol Oncol 12(2 Pt 2): S98-110, 1981.
26. Herbst AL: Diethylstilbestrol and other sex hormones during pregnancy. Obstet Gynecol 58(5 Suppl): 35S-40S, 1981.
27. Harris RW, Brinton LA, Cowdell RH, Skegg DC, Smith PG, Vessey MP and Doll R: Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. Br J Cancer 42(3): 359-369, 1980.
28. Hellberg D, Valentin J and Nilsson S: Long-term use of oral contraceptives and cervical neoplasia: an association confounded by other risk factors? Contraception 32(4): 337-346, 1985.
29. Donnan SP, Wong FW, Ho SC, Lau EM, Takashi K and Esteve J: Reproductive and sexual risk factors and human papilloma virus infection in cervical cancer among Hong Kong Chinese. Int J Epidemiol 18(1): 32-36, 1989.
30. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M and Dusek L: Hormonal contraception and risk of cancer. Hum Reprod Update 16(6): 631-650, 2010.
31. Moodley M, Moodley J, Chetty R, and Herrington CS: The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 13(2): 103-110, 2003.
32. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, Franceschi S and Beral V: Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361(9364): 1159-1167, 2003.
33. Samir R, Asplund A, Tot T, Pekar G and Hellberg D: High-Risk HPV Infection and CIN Grade Correlates to the Expression of c-myc, CD4+, FHIT, E-cadherin, Ki-67, and p16INK4a. J Low Genit Tract Dis, 2011.
34. Sikstrom B, Hellberg D, Nilsson S, Brihmer C and Mardh PA: Contraceptive use and reproductive history in women with cervical human papillomavirus infection. Adv Contracept 11(4): 273-284, 1995.
35. Silins I, Kallings I and Dillner J: Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 9(9): 953-959, 2000.
36. Veress G, Csiky-Meszaros T, Czegledy J and Gergely L: Oral contraceptive use and human papillomavirus infection in women without abnormal cytological results. Med Microbiol Immunol 181(4): 181-189, 1992.
37. Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RG, Studentsov YY, McAdams M and Schiffman M: A casecontrol study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev 13(10): 1574-1582, 2004.
38. Lacey JV Jr., Brinton LA, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Kurman RJ and Hildesheim A: Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 77(1): 149-154, 2000.
39. Shapiro S: Oral oestrogen-progestagen contraceptives, menopausal treatment, and cancer. Lancet Oncol 6 (10): 736; author reply 7, 2005.
40. Ploch E: Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 26(2): 169-177, 1987.
41. Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M and Sweetland S: Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370(9599): 1609-1621, 2007.
42. Shapiro S, Rosenberg L, Hoffman M, Kelly JP, Cooper DD, Carrara H, Denny LE, du Toit G, Allan BR, Stander IA and Williamson AL: Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control 14 (5): 485-495, 2003.
43. Hoyo C, Cousins DS, Bisgrove EZ, Gaines MM, Schwingl PJ and Fortney JA: Depo medroxyprogesterone acetate (DMPA) and combined oral contraceptives and cervical carcinoma in situ in women aged 50 years and under. West Indian Med J 53(6): 406-412, 2004.
44. Invasive cervical cancer and combined oral contraceptives. WHO collaborative study of neoplasia and steroid contraceptives. Br Med J (Clin Res Ed) 290 (6473): 961-965, 1985.
45. Lindstrom AK, Stendahl U, Tot T and Hellberg D: Associations between ten biological tumor markers in squamous cell cervical cancer and serum estradiol, serum progesterone and smoking. Anticancer Res 27(3B): 1401-1406, 2007.
46. Kim SH, Hur YJ, Lee SJ, Kim SJ, Park CG, Oh YK, Jung WW, Seo JB, Nam MH, Choi I and Chun T: E6 and E7 fusion immunoglobulin from human papilloma virus 16 induces dendritic cell maturation and antigen specific activation of T helper 1 response. Biotechnol Lett 33(4): 663-671, 2011.
47. Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Grigsby PW, Massad LS, Hernandez E, Judson PL, Swisher EM, Crowder S, Li J, Gerhard DS and Rader JS: CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res 67(23): 11202-11208, 2007.
48. Abrams ET and Miller EM: The roles of the immune system in women's reproduction: evolutionary constraints and life history trade-offs. Am J Phys Anthropol 146(Suppl 53): 134-154, 2011.
49. Schuurs AH and Verheul HA: Effects of gender and sex steroids on the immune response. J Steroid Biochem 35(2): 157-172, 1990.
50. Drill VA: Evaluation of the carcinogenic effects of estrogens, progestins and oral contraceptives on cervix, uterus and ovary of animals and man. Arch Toxicol Suppl 2: 59-84, 1979.
51. Arbeit JM, Howley PM and Hanahan D: Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci USA 93(7): 2930-2935, 1996.
52. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ and Arbeit JM: Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 60(5): 1267-1275, 2000.
53. Shai A, Brake T, Somoza C and Lambert PF: The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 67(4): 1626-1635, 2007.
54. Reboud S and Pageaut G: Topographical response and epithelial abnormalities of the mouse cervix after parenteral administration of progestational compounds. Contraception 16(4): 357-366, 1977.
55. Pater A, Bayatpour M and Pater MM: Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. Am J Obstet Gynecol 162(4): 1099-1103, 1990.
56. Chan WK, Klock G and Bernard HU: Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 63(8): 3261-3269, 1989.
57. Yuan F, Auborn K and James C: Altered growth and viral gene expression in human papillomavirus type 16-containing cancer cell lines treated with progesterone. Cancer Invest 17(1): 19-29, 1999.
58. Li L, Da J, Landstrom M, Ulmsten U and Fu X: Antiproliferative activity and toxicity of 2-methoxyestradiol in cervical cancer xenograft mice. Int J Gynecol Cancer 15(2): 301-307, 2005.
59. Mitrani-Rosenbaum S, Tsvieli R, and Tur-Kaspa R: Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol 70(Pt 8): 2227-2232, 1989.
60. Li L, Bu S, Backstrom T, Landstrom M, Ulmsten U and Fu X: Induction of apoptosis and G2/M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells. Anticancer Res 24 (2B): 873-880, 2004.
61. Correa I, Cerbon MA, Salazar AM, Solano JD, Garcia-Carranca A and Quintero A: Differential p53 protein expression level in human cancer-derived cell lines after estradiol treatment. Arch Med Res 33(5): 455-459, 2002.
62. Li Y and Pu D: The expression of cyclooxygenase-2 in cervical cancers and Hela cells was regulated by estrogen/progestogen. J Huazhong Univ Sci Technolog Med Sci 27(4): 457-460, 2007.
63. Lindstrom A, Backstrom T, Hellberg D, Tribukait B, Strang P and Stendahl U: Correlations between serum progesterone and smoking, and the growth fraction of cervical squamous cell carcinoma. Anticancer Res 20(5C): 3637-3640, 2000.
64. Hellberg D, Lindstrom AK and Stendahl U: Correlation between serum estradiol/progesterone ratio and survival length in invasive squamous cell cervical cancer. Anticancer Res 25(1B): 611-616, 2005.
65. Shields TS, Falk RT, Herrero R, Schiffman M, Weiss NS, Bratti C, Rodriguez AC, Sherman ME, Burk RD and Hildesheim A: A case-control study of endogenous hormones and cervical cancer. Br J Cancer 90(1): 146-152, 2004.
66. Kedzia W, Gozdzicka-Jozefiak A, Kwasniewska A, Schmidt M, Miturski R and Spaczynski M: Relationship between HPV infection of the cervix and blood serum levels of steroid hormones among pre- and postmenopausal women. Eur J Gynaecol Oncol 21(2): 177-179, 2000.
67. Salazar EL, Mercado E, Sojo I and Salcedo M: Relationship between estradiol 16 alpha-hydroxylation and human papillomavirus infection in cervical cell transformation. Gynecol Endocrinol 15(5): 335-340, 2001.
68. Lindstrom AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H and Hellberg D: LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 18(2): 312-317, 2008.
69. Hellberg D, Tot T and Stendahl U: Differences in expression of tumor markers between pre- and postmenopausal women with invasive cervical cancer. Anticancer Res 28(3B): 1793-1795, 2008.
70. Samir R, Tot T, Asplund A, Pekar G and Hellberg D: Increased serum progesterone and estradiol correlate to increased COX-2 tissue expression in cervical intraepithelial neoplasia. Anticancer Res 30(4): 1217-1222, 2010.
71. Shen K, Yueng W and Ngan H: Estrogen and progesterone receptors in normal cervix and primary cervical carcinoma. Chin Med J (Engl) 107(9): 648-652, 1994.
72. Konishi I, Fujii S, Nonogaki H, Nanbu Y, Iwai T and Mori T: Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer 68(6): 1340-1350, 1991.
73. Bekkers RL, van der Avoort IA, Melchers WJ, Bulten J, de Wilde PC and Massuger LF: Down regulation of estrogen receptor expression is an early event in human papillomavirus infected cervical dysplasia. Eur J Gynaecol Oncol 26(4): 376-382, 2005.
74. Potish RA, Twiggs LB, Adcock LL, Prem KA, Savage JE and Leung BS: Prognostic importance of progesterone and estrogen receptors in cancer of the uterine cervix. Cancer 58(8): 1709-1713, 1986.
75. Twiggs LB, Potish RA, Leung BS, Carson LF, Adcock LL, Savage JE and Prem KA: Cytosolic estrogen and progesterone receptors as prognostic parameters in stage IB cervical carcinoma. Gynecol Oncol 28(2): 156-160, 1987.
76. Martin JD, Hahnel R, McCartney AJ and De Klerk N: The influence of estrogen and progesterone receptors on survival in patients with carcinoma of the uterine cervix. Gynecol Oncol 23(3): 329-335, 1986.
77. Hunter RE, Longcope C and Keough P: Steroid hormone receptors in carcinoma of the cervix. Cancer 60(3): 392-396, 1987.
78. Noel JC, Bucella D, Fayt I, Simonart T, Buxant F, Anaf V and Simon P: Androgen receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Int J Gynecol Pathol 27(3): 437-441, 2008.
79. Green J, Berrington de Gonzalez A, Smith JS, Franceschi S, Appleby P, Plummer M and Beral V: Human papillomavirus infection and use of oral contraceptives. Br J Cancer 88(11): 1713-1720, 2003.
80. Syrjanen K, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J, Podistov J, Chemeris G, Sozaeva L, Lipova E, Tsidaeva I, Ivanchenko O, Pshepurko A, Zakharenko S, Nerovjna R, Kljukina L, Erokhina O, Branovskaja M, Nikitina M, Grunberga V, Grunberg A, Juschenko A, Santopietro R, Cintorino M, Tosi P and Syrjanen S: Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections. Anticancer Res 26(6C): 4729-4740, 2006.
81. Mittal R, Tsutsumi K, Pater A and Pater MM: Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 81(1): 5-12, 1993.
82. Khare S, Pater MM, Tang SC and Pater A: Effect of glucocorticoid hormones on viral gene expression, growth, and dysplastic differentiation in HPV16-immortalized ectocervical cells. Exp Cell Res 232(2): 353-360, 1997.
83. Morales-Peza N, Auewarakul P, Juarez V, Garcia-Carranca A and Cid-Arregui A: In vivo tissue-specific regulation of the human papillomavirus type 18 early promoter by estrogen, progesterone, and their antagonists. Virology 294(1): 135-140, 2002.
84. Bartholomew JS, Glenville S, Sarkar S, Burt DJ, Stanley MA, Ruiz-Cabello F, Chengang J, Garrido F and Stern PL: Integration of high-risk human papillomavirus DNA is linked to the downregulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells. Cancer Res 57(5): 937-942, 1997.
85. Zheng J: Sex hormones are weak regulators of HPV16 DNA-immortalized human uterine exocervical epithelial cells. Chin Med J (Engl) 111(4): 364-367, 1998.
86. Ruutu M, Wahlroos N, Syrjanen K, Johansson B and Syrjanen S: Effects of 17beta-estradiol and progesterone on transcription of human papillomavirus 16 E6/E7 oncogenes in CaSki and SiHa cell lines. Int J Gynecol Cancer 16(3): 1261-1268, 2006.
87. Dziubinska-Parol I, Gasowska U, Rzymowska J and Kwasniewska A: Influence of physiologic 17 beta-estradiol concentrations on gene E6 expression in HVP type 18 in vitro. Ginekol Pol 74(9): 710-713, 2003.
88. Webster K, Taylor A and Gaston K: Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 E2 and E7 proteins. J Gen Virol 82(Pt 1): 201-213, 2001.
89. Lindstrom AK, Tot T, Stendahl U, Syrjanen S, Syrjanen K and Hellberg D: Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer. Anticancer Res 29(7): 2577-2578, 2009.
90. Suzuki Y, Nakano T, Arai T, Morita S, Tsujii H and Oka K: Progesterone receptor is a favorable prognostic factor of radiation therapy for adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 47(5): 1229-1234, 2000.
91. Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R and Bodner-Adler B: Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res 30(4): 1341-1345, 2010.
92. Ursin G, Peters RK, Henderson BE, d'Ablaing G, 3rd, Monroe KR and Pike MC: Oral contraceptive use and adenocarcinoma of cervix. Lancet 344(8934): 1390-1394, 1994.
93. Lacey JV Jr., Brinton LA, Abbas FM, Barnes WA, Gravitt PE, Greenberg MD, Greene SM, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Silverberg SG and Hildesheim A: Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 8(12): 1079-1085, 1999.
94. Madeleine MM, Daling JR, Schwartz SM, Shera K, McKnight B, Carter JJ, Wipf GC, Critchlow CW, McDougall JK, Porter P and Galloway DA: Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev 10(3): 171-177, 2001.
95. Chung SH and Lambert PF: Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc Natl Acad Sci USA 106(46): 19467-72, 2009.
96. Yuan F, Chen DZ, Liu K, Sepkovic DW, Bradlow HL and Auborn K: Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res 19(3A): 1673-1680, 1999.
97. Suh-Burgmann E, Sivret J, Duska LR, Del Carmen M and Seiden MV: Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - a pilot study. Gynecol Obstet Invest 55(1): 25-31, 2003.
98. Hefler L, Grimm C, Tempfer C and Reinthaller A: Treatment with vaginal progesterone in women with low-grade cervical dysplasia: a phase II trial. Anticancer Res 30(4): 1257-1261, 2010.